Expanded indication builds on existing U.S. FDA approval of mRESVIA for adults aged 60 and older CAMBRIDGE, MA / ACCESS ...

The U.S. Food and Drug Administration (FDA) has expanded the use of Modernas (NASDAQ:MRNA) RSV vaccine, mRESVIA, to adults aged 18 to 59 who are at increased risk of respiratory syncytial virus (RSV) ...

The shot is approved for the prevention of RSV-associated lower respiratory tract disease in adults aged 60 or older. Read more at straitstimes.com. Read more at straitstimes.com.

Moderna said the Food and Drug Administration expanded its approval of the pharmaceutical company's respiratory syncytial virus vaccine, mResvia, to adults aged 18-59 at increased risk for the disease ...

Expanded indication builds on existing U.S. FDA approval of mRESVIA for adults aged 60 and older CAMBRIDGE, MA / ACCESS Newswire / June 12, 2025 / Moderna, Inc. (NASDAQ:MRNA) today announced that the ...

Rep Kim Schrier, MD, (D-Wash.), said on X yesterday that some of the newly appointed ACIP replacements are anti-vaccine ...

A newly approved shot could soon help protect babies from respiratory syncytial virus (RSV), the top cause of hospitalization ...

Scientists and analysts express concern that the newly appointed members—which include known anti-vaxxers—could relitigate ...

The Food and Drug Administration has approved a new drug from Merck designed to protect infants from respiratory syncytial ...